The broad-spectrum antitumor action of cyclosporin A is due to its tachykinin receptor antagonist pharmacological profile

Peptides

Volumn 31, Issue 9, 2010, Pages 1643-1648

  Muñoz, Miguel ^a   Rosso, Marisa ^a   González, Ana ^a   Saenz, Javier ^a   Coveñas, Rafael ^b  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

Apoptosis; Carcinoma; Cyclosporin A; Glioma; Neuroblastoma; Retinoblastoma

Indexed keywords

CYCLOSPORIN A; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; SUBSTANCE P; TACHYKININ RECEPTOR; TACHYKININ RECEPTOR ANTAGONIST;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL VIABILITY; COLON CARCINOMA; CONCENTRATION RESPONSE; DRUG RECEPTOR BINDING; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; LARYNX CARCINOMA; NEUROBLASTOMA; PANCREAS CARCINOMA; PRIORITY JOURNAL; RETINOBLASTOMA; STOMACH CARCINOMA;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; CYCLOSPORINE; HEK293 CELLS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INHIBITORY CONCENTRATION 50; NEOPLASMS, GLANDULAR AND EPITHELIAL; RECEPTORS, NEUROKININ-1; RECEPTORS, TACHYKININ; SUBSTANCE P;

EID: 77955657413     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2010.06.002     Document Type: Article

References (44)

1. R. Bang, G. Sass, A.K. Kiemer, A.M. Vollmar, W.L. Neuhuber, and G. Tiegs Neurokinin-1 receptor antagonists CP-96,345 and l-733,060 protect mice from cytokine-mediated liver injury J Pharmacol Exp Ther 305 2003 31 39
2. M. Bigioni, A. Benzo, C. Irrissuto, C.A. Maggi, and C. Goso Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231 Anticancer Drugs 16 2005 1083 1089
3. J.F. Borel, C. Feurer, H.U. Gubler, and H. Stahelin Biological effects of cyclosporin A: a new anti-lymphocyte agent Agents Actions 6 1976 468 475
4. L. Drew, N. Groome, T.J. Hallam, J.R. Warr, and M.G. Rumsby Changes in protein kinase C subspecies protein expression and activity in a series of multidrug-resistant human KB carcinoma cell lines Oncol Res 6 1994 429 438
5. F. Esteban, M.A. González-Moles, D. Castro, M.M. Martín-Jaén, M. Redondo, and I. Ruiz-Avila Expression of substance P and neurokinin-1-receptor in laryngeal cancer: linking chronic inflammation to cancer promotion and progression Histopathology 54 2009 258 260
6. F. Esteban, M. Muñoz, M.A. González-Moles, and M. Rosso A role for substance P in cancer promotion and progression: a mechanism to counteract intracellular death signals following oncogene activation or DNA damage Cancer Metastasis Rev 25 2006 137 145
7. H. Friess, Z. Zhu, V. Liard, X. Shi, S.V. Shrikhande, and L. Wang Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer Lab Invest 83 2003 731 742
8. G.A.M. Giardina, S. Gagliardi, and M. Martinelli Antagonists at the neurokinin receptors - recent patent literature Drugs 6 2003 758 772 (Pubitemid 37086786)
9. B.D. Gitter, D.C. Waters, P.G. Threlkeld, A.M. Lovelace, K. Matsumoto, and R.F. Bruns Cyclosporin A is a substance P (tachykinin NK1) receptor antagonist Eur J Pharmacol 289 1995 439 446
10. S. Harrison, P. Geppetti, and P. Substance Int J Biochem Cell Biol 33 2001 555 576
11. I.M. Hennig, J.A. Laissue, U. Horisberger, and J.C. Reubi Substance-P receptors in human primary neoplasms: tumoral and vascular localization Int J Cancer 61 1995 786 792
12. T. Hökfelt, B. Pernow, and J. Wahren Substance P: a pioneer amongst neuropeptides J Intern Med 249 2001 27 40
13. Y.P. Hu, and J. Robert Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance J Cancer Res Clin Oncol 123 1997 201 210
14. M.S. Kramer, N. Cutler, J. Feighner, R. Shrivastava, J. Carman, and J.J. Sramek Distinct mechanism for antidepressant activity by blockade of central substance P receptors Science 281 1998 1640 1645
15. K. Lang, T.L. Drell, A. Lindecke, B. Niggemann, C. Kaltschmidt, and K.S. Zaenker Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs Int J Cancer 112 2004 231 238
16. W. Luo, T.R. Sharif, and M. Sharif Substance P-induced mitogenesis in human astrocytoma cells correlates with activation of the mitogen-activated protein kinase signaling pathway Cancer Res 56 1996 4983 4991
17. J. Meador, P. Sweet, M. Stupecky, M.W. Wetzel, S. Murray, and S. Gupta Enhancement by cyclosporin A of daunorubicin efficacy in Ehrlich ascites carcinoma and murine hepatoma 129 Cancer Res 47 1987 6216 6219
18. M. Muñoz, A. Pérez, R. Coveñas, M. Rosso, and E. Castro Antitumoural action of l-733,060 on neuroblastoma and glioma cell lines Arch Ital Biol 142 2004 105 112
19. M. Muñoz, A. Pérez, M. Rosso, C. Zamarriego, and R. Rosso Antitumoural action of NK1 receptor antagonist l-733,060 on human melanoma cell lines Melanoma Res 14 2004 183 188
20. M. Muñoz, and M. Rosso The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug Invest New Drugs 28 2010 187 193
21. M. Muñoz, M. Rosso, F.J. Aguilar, M.A. González-Moles, M. Redondo, and F. Esteban NK-1 receptor antagonists induce apoptosis and counteract substance P-related mitogenesis in human laryngeal cancer cell line HEp-2 Invest New Drugs 26 2008 111 118
22. M. Muñoz, M. Rosso, and R. Coveñas The NK-1 receptor is involved in the antitumoural action of l-733,060 and in the mitogenic action of substance P on human pancreatic cancer cell lines Lett Drug Des Discov 3 2006 323 329
23. M. Muñoz, M. Rosso, and R. Coveñas NK-1 receptor antagonists as new anti-tumoural agents: action on human neuroblastoma cell lines J.A. Fernandes, Focus on neuroblastoma research 2007 Nova Science Publishers New York 31 56
24. M. Muñoz, M. Rosso, and R. Coveñas A new frontier in the treatment of cancer: NK-1 receptor antagonists Curr Med Chem 17 2010 504 516
25. M. Muñoz, M. Rosso, R. Coveñas, I. Montero, and M.A. González-Moles Neurokinin-1 receptors located in human retinoblastoma cell lines: antitumor action of its antagonists, l-732,138 Invest Ophthalmol Vis Sci 48 2007 2775 2781
26. M. Muñoz, M. Rosso, A. Pérez, R. Coveñas, R. Rosso, and C. Zamarriego The NK1 receptor is involved in the antitumoural action of l-733,060 and the mitogenic action of substance P on neuroblastoma and glioma cell lines Neuropeptides 39 2005 427 432
27. M. Muñoz, M. Rosso, A. Pérez, R. Coveñas, R. Rosso, and C. Zamarriego Antitumoral action of the neurokinin-1-receptor antagonist l-733,060 and mitogenic action of substance P on human retinoblastoma cell lines Invest Ophthalmol Vis Sci 46 2005 2567 2570 (Pubitemid 43119507)
28. Muñoz M, Rosso M, Robles-Frías MJ, Salinas-Martín MV, Coveñas R. Immunolocalization of the neurokinin-1 receptor: a new target in the treatment of human malignant melanoma. Lab Invest, in press, doi:10.1038/labinvest.2010.102.
29. M. Muñoz, M. Rosso, J.A. Soult, and R. Coveñas Antitumoural action of neurokinin-1 receptor antagonists on human brain cancer cell lines A.V. Yang, Brain cancer: therapy and surgical intervention 2006 Nova Science Publishers New York 45 75
30. Y. Nishizuka, M.S. Shearman, T. Oda, N. Berry, T. Shinomura, and Y. Asaoka Membrane phospholipid degradation and protein kinase C for cell signalling Neurosci Res 15 1992 3 5
31. C. Palma, M. Bigioni, C. Irrissuto, F. Nardelli, C.A. Maggi, and S. Manzini Anti-tumour activity of tachykinin NK1 receptor antagonists on human glioma U373 MG xenograft Br J Cancer 82 2000 480 487
32. M. Piontek, and R. Porschen Growth inhibition of human gastrointestinal cancer cells by cyclosporin A J Cancer Res Clin Oncol 120 1994 695 699
33. M. Qadyr, K.L. OLoughlin, S.M. Frivke, N.A. Williamson, W.R. Greco, and H. Minderman Cyclosporin A is a broad-spectrum multidrug resistance modulator Clin Cancer Res 11 2005 2320 2326
34. 11] Substance P induces apoptosis in lung cancer cell lines in vitro Biochem Biophys Res Commun 199 1994 1313 1319
35. M. Rosso, M.J. Robles-Frías, R. Coveñas, M.V. Salinas-Martín, and M. Muñoz The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of l-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines Tumor Biol 29 2008 245 254
36. N.M. Rupniak, E. Carlson, S. Boyce, J.K. Webb, and R.G. Hill Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist l-733,060 in gerbils Pain 67 1996 189 195
37. 11] Substance P: a novel potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells Cancer Res 57 1997 51 54
38. D. Singh, D.D. Joshi, M. Hameed, J. Qian, P. Gascón, and P.B. Maloof Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis Proc Natl Acad Sci USA 97 2000 388 393
39. L. Slater, M. Sweet, M. Stupecky, and S. Gupka Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro J Clin Invest 77 1986 1405 1408
40. S. Stabel, and P.J. Parker Protein kinasa C Pharmacol Ther 51 1991 71 95
41. F.D. Tattersall, W. Rycroft, M. Cumberbatch, G. Mason, S. Tye, and D.J. Williamson The novel NK-1 receptor antagonist MK-0869 (l-754,030) and its water soluble phosphoryl prodrug, l-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets Neuropharmacology 39 2000 652 663
42. P.R. Twentyman, N.E. Fox, and D.J.G. White Cyclosporin A and its analogs as modifiers of adriamycin and vincristine resistance in a multi-drug resistant human lung cancer cell line Br J Cancer 56 1987 55 57
43. G.B. Varty, M.E. Cohen-Williams, C.A. Morgan, U. Pylak, R.A. Duffy, and J.E. Lachowicz The gerbil elevated plus-maze II: anxiolytic-like effects of selective neurokinin NK1 receptor antagonists Neuropsychopharmacology 27 2002 371 379
44. M. Ziche, L. Morbidelli, M. Pacini, P. Gepetti, G. Alessandri, and C.A. Maggi Substance P stimulates neovascularization in vivo and proliferation of cultured endothelial cells Microvasc Res 40 1990 264 278